Attend virtual education event for gynecologic cancer care

March 24, 2022 Providence Cancer Institute of Oregon

Join Andrea Hardy, RN, BSN, Providence gynecologic oncology nurse care coordinator, on March 9 for Coping with Chemotherapy. This is a free, virtual educational event for gynecologic cancer patients and their caregivers presented by the Ovarian Cancer Alliance of Oregon & SW Washington in collaboration with Providence Cancer Institute of Oregon.

Andrea will help empower patients to take an active role in their own health care by helping them understand chemotherapy and its side effects, both physically and emotionally.

Topics will include:

Taking an active role in your care
Understanding chemotherapy
Most common types of chemotherapy, including immunotherapy and oral PARP inhibitors
Understanding and managing the side effects of chemotherapy
Communicating with your health care team

Event details

Wednesday, March 9, 2022

5:00 p.m. - 6:15 p.m. PT

Register here

About the presenter

Andrea Hardy, RN, BSN, is a Gynecologic Oncology Nurse Care Coordinator at Providence Cancer Institute of Oregon. She cares for patients with gynecologic cancer throughout their diagnosis, treatment, and survivorship. Among her various nursing services, Andrea provides patient education for symptom management over the course of treatments, starting with chemotherapy. This support helps to ease the journey into the unknown and empowers patients to participate in their own health care.

About the Providence Gynecologic Oncology Program

The Providence Gynecologic Cancer Program provides highly specialized care for patients diagnosed with ovarian, cervical, uterine, vaginal, vulvar and other female reproductive tract cancers, as well as pre-cancerous conditions. Patients receive advanced treatments, from robotic surgery to immunotherapy, with the opportunity to participate in clinical trials. To learn more, visit ProvidenceOregon.org/gyncancer.

Related resources

Gynecologic oncology care now available at Providence Cancer Institute

Clinical trial aims to help premenopausal women at risk for ovarian cancer

Phase II study of neoadjuvant combination therapy for ovarian cancer

Welcome to your journey for creating a healthier you

Attend virtual education event for gynecologic cancer care

Previous Article

Next Article

Attend virtual education event for gynecologic cancer care

Previous Article

Next Article

Other content in this Stream

Real-world data from Providence, Illumina and Microsoft Research finds cancer patients with early genomic testing received better precision treatment, underlines urgency to become standard practice

R. Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed) has accepted the roles of executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute.

The annual SITC meeting brings together cancer immunotherapy researchers with a goal to advance science, discover breakthroughs and educate the world on cancer immunotherapy.

New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.

Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.

Providence Cancer Institute in partnership with AIM at Melanoma present a free online event designed to educate and empower patients and care partners affected by melanoma.

A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.

Dr. Allie Grossmann’s new lab at Earle A. Chiles Research Institute is focused on understanding how tumors communicate with their environment, grow, survive and spread.

Dr. Walter Urba, a pioneer and key figure in the development of immunotherapy, will retire from Providence Cancer Institute at the end of year.

Prominent cancer scientist Dr. Bernard Fox recognized for his work to advance the field of cancer immunotherapy through increasing public understanding, awareness and research efforts.

A new medication may help people with KRAS G12C-mutant non-small cell lung cancer. Read about the study and a trial evaluating an immunotherapy for treating head and neck squamous cell carcinoma.

Cancer survivor Mark Williams chats with Dr. Brendan Curti about

What motivates the co-captains of the FINISHCANCER caregiver team to commit their time to running this remarkable relay? Read what they say about preparing for the race and what inspires them to run.

Although chemotherapy is the cornerstone treatment for triple negative breast cancer, survival outcomes remain disappointing. Two studies could help improve treatment options.

A study designed to treat recurrent epithelial ovarian cancer looks at an antibody drug conjugate, and a second study for people with advanced breast cancer evaluates a drug that degrades estrogen rec

Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.

June is National Cancer Survivor Month, but we honor people with cancer, no matter where they are on their journey, every day of the year. Find out about the survivorship program at Providence Cancer

Providence Cancer Institute presented a free virtual education event about MRI-guided radiation therapy and how it is used to treat pancreatic cancer.

The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.

A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model has been published in Nature.